These comprehensive analyses from our in-house cohort confirm the role of FLAD1 as a critical biomarker in HCC, highlighting its potential clinical significance in the context of liver cancer diagnostics and treatment planning. This evidence concerns the gene FLAD1 and hepatocellular carcinoma.